PharmaCyte Biotech (PMCB) Non-Current Assets (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Non-Current Assets of $9.3 million for Q2 2026, down 71.54% year-over-year from $32.8 million in Q2 2025, and down 73.47% quarter-over-quarter from $35.2 million in Q1 2026.
PharmaCyte Biotech (PMCB) Non-Current Assets (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Non-Current Assets for 16 consecutive years, with $9.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets fell 71.54% year-over-year to $9.3 million; the TTM figure through Apr 2026 stood at $9.3 million (down 71.54% YoY), while the FY2026 annual figure was $9.3 million, down 71.54% from the prior year.
- Non-Current Assets retreated to $9.3 million in Q2 2026 per PMCB's latest filing, from $35.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $37.3 million in Q3 2024 and bottomed at $5.1 million in Q1 2022.
- Historically, Non-Current Assets has averaged $16.4 million across 5 years, with a median of $9.4 million in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Assets surged 627.57% — and 2026, when it tumbled 71.54%.
- PharmaCyte Biotech's Non-Current Assets stood at $5.1 million in 2022, then changed by 0.0% to $5.1 million in 2023, then soared by 558.28% to $33.8 million in 2024, then dropped by 2.4% to $33.0 million in 2025, then sank by 71.68% to $9.3 million in 2026.
- Business Quant data shows PMCB's Non-Current Assets at $9.3 million in Q2 2026, $35.2 million in Q1 2026, and $33.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 18.06 Bn |
| 10 | PharmaCyte Biotech | 4.36 Mn | 4.36 Mn | - | 9.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 9.33 Mn |
| Jan 31, 2026 | 35.18 Mn |
| Oct 31, 2025 | 32.95 Mn |
| Jul 31, 2025 | 26.00 Mn |
| Apr 30, 2025 | 32.79 Mn |
| Jan 31, 2025 | 26.87 Mn |
| Oct 31, 2024 | 33.77 Mn |
| Jul 31, 2024 | 37.32 Mn |
| Apr 30, 2024 | 9.46 Mn |
| Jan 31, 2024 | 9.85 Mn |
| Oct 31, 2023 | 5.13 Mn |
| Jul 31, 2023 | 5.13 Mn |
| Apr 30, 2023 | 5.13 Mn |
| Jan 31, 2023 | 5.13 Mn |
| Oct 31, 2022 | 5.13 Mn |
| Jul 31, 2022 | 5.13 Mn |
| Apr 30, 2022 | 5.13 Mn |
| Jan 31, 2022 | 5.13 Mn |
| Oct 31, 2021 | 5.13 Mn |
| Jul 31, 2021 | 5.13 Mn |